Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Fatma E. El-Khouly"'
Autor:
Maria Wiese, Bente Pohlmeier, Klaudia Kubiak, Fatma E. El-Khouly, Maren Sitte, Angel M. Carcaboso, Joshua N. Baugh, Thomas Perwein, Gunther Nussbaumer, Michael Karremann, Gerrit H. Gielen, Gabriela Salinas, Christof M. Kramm
Publikováno v:
Journal of Traditional and Complementary Medicine, Vol 14, Iss 1, Pp 101-108 (2024)
Background and aim: Pediatric high-grade gliomas (pedHGG) comprise a very poor prognosis. Thus, parents of affected children are increasingly resorting to complementary and alternative medicine (CAM), among those Boswellia extracts. However, nothing
Externí odkaz:
https://doaj.org/article/7382fc51cc334184815e639748ac5cbb
Autor:
Fatma E. El-Khouly, Rianne Haumann, Marjolein Breur, Sophie E.M. Veldhuijzen van Zanten, Gertjan J.L. Kaspers, N. Harry Hendrikse, Esther Hulleman, Dannis G. van Vuurden, Marianna Bugiani
Publikováno v:
Free Neuropathology, Vol 2 (2021)
Aims: Diffuse intrinsic pontine glioma (DIPG) is a childhood brainstem tumor with a median overall survival of eleven months. Lack of chemotherapy efficacy may be related to an intact blood-brain barrier (BBB). In this study we aim to investigate the
Externí odkaz:
https://doaj.org/article/8364693f31c04d428fb0151b61df7ea3
Autor:
Fatma E. El-Khouly, Dannis G. van Vuurden, Thom Stroink, Esther Hulleman, Gertjan J. L. Kaspers, N. Harry Hendrikse, Sophie E. M. Veldhuijzen van Zanten
Publikováno v:
Frontiers in Oncology, Vol 7 (2017)
Despite decades of clinical trials for diffuse intrinsic pontine glioma (DIPG), patient survival does not exceed 10% at two years post-diagnosis. Lack of benefit from systemic chemotherapy may be attributed to an intact bloodbrain barrier (BBB). We a
Externí odkaz:
https://doaj.org/article/4a322cdbe4634fe9a7b23ba068755009
Autor:
Syed M Adil, Maria Wiese, N. Harry Hendrikse, Esther Hulleman, Christof M. Kramm, Gertjan J.L. Kaspers, Sophie E. M. Veldhuijzen van Zanten, Dannis G. van Vuurden, Fatma E El-Khouly
Publikováno v:
Pediatric Blood and Cancer, 68(9):e29061. Wiley-Liss Inc.
el-Khouly, F E, Adil, S M, Wiese, M, Hulleman, E, Hendrikse, N H, Kaspers, G J L, Kramm, C M, SIOPE DIPG Network, Veldhuijzen van Zanten, S E M & van Vuurden, D G 2021, ' Complementary and alternative medicine in children with diffuse intrinsic pontine glioma—A SIOPE DIPG Network and Registry study ', Pediatric Blood and Cancer, vol. 68, no. 9, e29061 . https://doi.org/10.1002/pbc.29061
el-Khouly, F E, Adil, S M, Wiese, M, Hulleman, E, Hendrikse, N H, Kaspers, G J L, Kramm, C M, SIOPE DIPG Network, Veldhuijzen van Zanten, S E M & van Vuurden, D G 2021, ' Complementary and alternative medicine in children with diffuse intrinsic pontine glioma—A SIOPE DIPG Network and Registry study ', Pediatric Blood and Cancer, vol. 68, no. 9, e29061 . https://doi.org/10.1002/pbc.29061
Introduction: Diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive childhood brainstem malignancy with a 2-year survival rate of 2= 6.08, p =.014). No significant difference was found between CAM users and nonusers based on ethnicity (χ
Autor:
Fatma E El-Khouly, Sophie E. M. Veldhuijzen van Zanten, Esther Sanchez Aliaga, W. Peter Vandertop, Dannis G. van Vuurden, N. Harry Hendrikse, Dewi P. Bakker, Gertjan J.L. Kaspers, Marc H. A. Jansen
Publikováno v:
Journal of Neuro-Oncology, 153(2), 263-271. Kluwer Academic Publishers
Journal of Neuro-Oncology, 153(2), 263-271. Kluwer Academic
Journal of neuro-oncology, 153(2), 263-271. Kluwer Academic Publishers
Journal of Neuro-Oncology
El-Khouly, F E, Veldhuijzen van Zanten, S E M, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Hendrikse, N H, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2021, ' A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 153, no. 2, pp. 263-271 . https://doi.org/10.1007/s11060-021-03763-1
Journal of Neuro-Oncology, 153(2), 263-271. Kluwer Academic
Journal of neuro-oncology, 153(2), 263-271. Kluwer Academic Publishers
Journal of Neuro-Oncology
El-Khouly, F E, Veldhuijzen van Zanten, S E M, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Hendrikse, N H, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2021, ' A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 153, no. 2, pp. 263-271 . https://doi.org/10.1007/s11060-021-03763-1
Introduction This study investigates the safety, tolerability, and preliminary efficacy of combined treatment with VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan, and EGFR inhibitor erlotinib in children with progressive diffuse int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b5cd964c19a4c2c73e81b5e280ec0d5
https://research.vumc.nl/en/publications/99c311f6-a6ec-4c49-9b55-1e02e59d3bb6
https://research.vumc.nl/en/publications/99c311f6-a6ec-4c49-9b55-1e02e59d3bb6
Autor:
Esther Sanchez Aliaga, C. Michel Zwaan, Fatma E El-Khouly, Sophie E. M. Veldhuijzen van Zanten, W. Peter Vandertop, Dannis G. van Vuurden, Cornelis J.A. Haasbeek, Gertjan J.L. Kaspers, Marc H. A. Jansen, Dewi P. Bakker, Nicole I. Wolf
Publikováno v:
Journal of Neuro-Oncology
Journal of Neuro-Oncology, 135(2), 307-315. Kluwer Academic Publishers
Veldhuijzen van Zanten, S E M, El-Khouly, F E, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Haasbeek, C J A, Wolf, N I, Zwaan, C M, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2017, ' A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 135, no. 2, pp. 307-315 . https://doi.org/10.1007/s11060-017-2575-9
Journal of Neuro-Oncology, 135(2), 307-315. Kluwer Academic
Journal of neuro-oncology, 135(2), 307-315. Kluwer Academic Publishers
Journal of Neuro-Oncology, 135(2), 307-315. Kluwer Academic Publishers
Veldhuijzen van Zanten, S E M, El-Khouly, F E, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Haasbeek, C J A, Wolf, N I, Zwaan, C M, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2017, ' A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 135, no. 2, pp. 307-315 . https://doi.org/10.1007/s11060-017-2575-9
Journal of Neuro-Oncology, 135(2), 307-315. Kluwer Academic
Journal of neuro-oncology, 135(2), 307-315. Kluwer Academic Publishers
The purpose of this phase I/II, open-label, single-arm trial is to investigate the safety, tolerability, maximum tolerated dose and preliminary efficacy of the potential radiosensitizer gemcitabine, administered concomitantly to radiotherapy, in chil
Autor:
Halldora K. Thorarinsdottir, Geert O. Janssens, Ella Kumirova, Sophie E. M. Veldhuijzen van Zanten, Ulrich W. Thomale, Ingrid Torsvik, Virve Pentikäinen, Victor Calvagna, N. Harry Hendrikse, Giedre Rutkauskiene, Veronica Biassoni, Dannis G. van Vuurden, Vicente Santa-Maria Lopez, Fatma E El-Khouly, Maria Joao Gil-da-Costa, Stefan Holm, Simon Bailey, Kaie Pruunsild, Monika Drogosiewicz, Ofelia Cruz-Martinez, Jacques Grill, Gertjan J.L. Kaspers, Maura Massimino, David Sumerauer, Jane Pears, Peter Hauser, Lidija Kitanovski, G. Loizos, Christof M. Kramm, André O. von Bueren, Natacha Entz-Werle, Monica Dragomir, Antonis Kattamis, Karsten Nysom, Tim Hayden, Ladislav Deak, Irene Slavc, Rejin Kebudi, Sandra Jacobs, Enrique López Aguilar, Filip Jadrijevic-Cvrlje
Publikováno v:
Journal of Neuro-Oncology, 145(1), 177. Kluwer Academic Publishers
Journal of Neuro-Oncology
Journal of Neuro-Oncology, 145(1), 177-184. Kluwer Academic Publishers
el-Khouly, F E, Veldhuijzen van Zanten, S E M, Santa-Maria Lopez, V, Hendrikse, N H, Kaspers, G J L, Loizos, G, Sumerauer, D, Nysom, K, Pruunsild, K, Pentikainen, V, Thorarinsdottir, H K, Rutkauskiene, G, Calvagna, V, Drogosiewicz, M, Dragomir, M, Deak, L, Kitanovski, L, von Bueren, A O, Kebudi, R, Slavc, I, Jacobs, S, Jadrijevic-Cvrlje, F, Entz-Werle, N, Grill, J, Kattamis, A, Hauser, P, Pears, J, Biassoni, V, Massimino, M, Lopez Aguilar, E, Torsvik, I K, Joao Gil-da-Costa, M, Kumirova, E, Cruz-Martinez, O, Holm, S, Bailey, S, Hayden, T, Thomale, U W, Janssens, G O R, Kramm, C M & van Vuurden, D G 2019, ' Diagnostics and treatment of diffuse intrinsic pontine glioma : where do we stand? ', Journal of Neuro-Oncology, vol. 145, no. 1, pp. 177-184 . https://doi.org/10.1007/s11060-019-03287-9, https://doi.org/10.1007/s11060-019-03287-9
Journal of neuro-oncology, Vol. 145, No 1 (2019) pp. 177-184
Journal of Neuro-Oncology
Journal of Neuro-Oncology, 145(1), 177-184. Kluwer Academic Publishers
el-Khouly, F E, Veldhuijzen van Zanten, S E M, Santa-Maria Lopez, V, Hendrikse, N H, Kaspers, G J L, Loizos, G, Sumerauer, D, Nysom, K, Pruunsild, K, Pentikainen, V, Thorarinsdottir, H K, Rutkauskiene, G, Calvagna, V, Drogosiewicz, M, Dragomir, M, Deak, L, Kitanovski, L, von Bueren, A O, Kebudi, R, Slavc, I, Jacobs, S, Jadrijevic-Cvrlje, F, Entz-Werle, N, Grill, J, Kattamis, A, Hauser, P, Pears, J, Biassoni, V, Massimino, M, Lopez Aguilar, E, Torsvik, I K, Joao Gil-da-Costa, M, Kumirova, E, Cruz-Martinez, O, Holm, S, Bailey, S, Hayden, T, Thomale, U W, Janssens, G O R, Kramm, C M & van Vuurden, D G 2019, ' Diagnostics and treatment of diffuse intrinsic pontine glioma : where do we stand? ', Journal of Neuro-Oncology, vol. 145, no. 1, pp. 177-184 . https://doi.org/10.1007/s11060-019-03287-9, https://doi.org/10.1007/s11060-019-03287-9
Journal of neuro-oncology, Vol. 145, No 1 (2019) pp. 177-184
Introduction Diffuse intrinsic pontine glioma (DIPG) is a rare clinically, neuro-radiologically, and molecularly defined malignancy of the brainstem with a median overall survival of approximately 11 months. Our aim is to evaluate the current tendenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c4a1c7159536c1bc0c8d610250afc1
https://dspace.library.uu.nl/handle/1874/391428
https://dspace.library.uu.nl/handle/1874/391428
Autor:
Marianna Bugiani, Rianne Haumann, Gertjan J.L. Kaspers, Esther Hulleman, Marjolein Breur, N. Harry Hendrikse, Sophie E. M. Veldhuijzen van Zanten, Fatma E. El-Khouly, Dannis G. van Vuurden
Publikováno v:
Neuro-Oncology
Diffuse intrinsic pontine glioma (DIPG) is a childhood brainstem tumor with a median overall survival of eleven months. Lack of chemotherapy efficacy may be related to an intact blood-brain-barrier (BBB). In this study we aim to compare the neuro-vas
Autor:
Esther Hulleman, Dannis G. van Vuurden, Gertjan J.L. Kaspers, Harry Hendrikse, Sophie E. M. Veldhuijzen van Zanten, Fatma E El-Khouly, Rianne Haumann, Marjolein Breur, Marianna Bugiani
Publikováno v:
Neuro Oncol
INTRODUCTION Chemotherapy has been unsuccessful for pediatric diffuse midline glioma (DMG) most likely due to an intact blood-brain barrier (BBB). However, the BBB has not been characterized in DMG and therefore its implications for drug delivery are
Autor:
Esther Sanchez Aliaga, W. Peter Vandertop, Dannis G. van Vuurden, Gertjan J.L. Kaspers, Marc H. A. Jansen, Fatma E. El‑Khouly, Dewi P. Bakker, C. Michel Zwaan, Nicole I. Wolf, Sophie E. M. Veldhuijzen van Zanten, Cornelis J.A. Haasbeek
Publikováno v:
Journal of Neuro-Oncology, 136(1), 219-220. Kluwer Academic Publishers
Veldhuijzen van Zanten, S E M, El-Khouly, F E, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Haasbeek, C J A, Wolf, N I, Zwaan, C M, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2018, ' Correction to : A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 136, no. 1, pp. 219-220 . https://doi.org/10.1007/s11060-017-2636-0
Veldhuijzen van Zanten, S E M, El-Khouly, F E, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Haasbeek, C J A, Wolf, N I, Zwaan, C M, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2018, ' Correction to : A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 136, no. 1, pp. 219-220 . https://doi.org/10.1007/s11060-017-2636-0
In Table 2 of the original publication, there were errors in the baseline scores for the PedsQL TM 3.0 Cancer Module questionnaire, so a corrected version of Table 2 is shown in this erratum. In the subcategories of the PedsQL TM 3.0 Cancer Module qu